Related Experiment Video
Updated: Jun 27, 2025
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Immunotherapy for Head and Neck Squamous Cell Carcinoma: Present and Future Approaches and Challenges
Mark D Orland1, Fauzia Ullah2, Emrullah Yilmaz3
1Department of Internal Medicine, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.
Abstract:
Despite significant progress and improving outcomes in the management of head and neck squamous cell carcinoma (HNSCC), there are few effective treatment options for patients with recurrent or metastatic head and neck squamous cell carcinoma. The advent of immune checkpoint inhibitors has changed the treatment algorithm of head and neck squamous cell carcinoma and are approved in the frontline setting for recurrent and metastatic (R/M) head and neck squamous cell carcinomas. Although promising for some patients, most patients with R/M HNSCC do not derive clinical benefit from currently approved checkpoint inhibitors. Many studies are underway to identify the patient population that would benefit the most from immunotherapy as well as postimmunotherapy treatment failures, including novel combinations of immunomodulatory therapies. In this review, we summarize the clinical development of all major clinical trials of immunotherapy in HNSCC.
Insights
Immune checkpoint inhibitors offer new hope for recurrent head and neck squamous cell carcinoma (HNSCC) but benefit only a subset of patients. Research is ongoing to improve immunotherapy effectiveness and identify optimal treatment strategies for HNSCC.
Area of Science:
- Oncology
- Immunotherapy
- Head and Neck Cancer Research
Background:
- Head and neck squamous cell carcinoma (HNSCC) management has improved, yet effective treatments for recurrent or metastatic (R/M) disease remain limited.
- Immune checkpoint inhibitors (ICIs) represent a significant advancement, approved for frontline treatment of R/M HNSCC.
- However, many R/M HNSCC patients do not respond to current ICIs, highlighting a critical unmet need.
Purpose of the Study:
- To review the clinical development and major clinical trials of immunotherapies in HNSCC.
- To explore strategies for identifying patient populations most likely to benefit from immunotherapy.
- To examine approaches for managing post-immunotherapy treatment failures in HNSCC.
Main Methods:
- Comprehensive literature review of clinical trials involving immunotherapy for HNSCC.
- Analysis of data from major clinical trials focusing on efficacy and patient selection.
- Summary of ongoing research into novel combinations and treatment strategies.
Main Results:
- ICIs have altered the treatment landscape for R/M HNSCC.
- A significant proportion of patients do not achieve clinical benefit from current ICI therapies.
- Ongoing research focuses on predictive biomarkers and combination therapies to enhance ICI efficacy.
Conclusions:
- While ICIs have advanced R/M HNSCC treatment, further research is essential to broaden patient benefit.
- Identifying patient subgroups and overcoming resistance mechanisms are key priorities for future immunotherapy development in HNSCC.
- Novel therapeutic combinations hold promise for improving outcomes in patients with advanced HNSCC.
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...